The world’s first clinical trial designed to explore using a hallucinogen from magic mushrooms to treat people with depression has stalled because of British and European rules on the use of illegal drugs in research.
David Nutt, president of the British Neuroscience Association and professor of neuropsychopharmacology at Imperial College London, said he had been granted an ethical green light and funding for the trial, but regulations were blocking it.
"We live in a world of insanity in terms of regulating drugs," he told a neuroscience conference in London on Sunday.
He has previously conducted small experiments on healthy volunteers and found that psilocybin, the psychedelic ingredient in magic mushrooms, has the potential to alleviate severe forms of depression in people who don’t respond to other treatments.
Following these promising early results he was awarded a 550,000 pounds ($844,000) grant from the UK’s Medical Research Council to conduct a full clinical trial in patients.
But psilocybin is illegal in Britain, and under the United Nations 1971 Convention on Psychotropic Substances it is classified as a Schedule 1 drug - one that has a high potential for abuse and no recognized medical use.
This, Nutt explained, means scientists need a special license to use magic mushrooms for trials in Britain, and the manufacture of a synthetic form of psilocybin for use in patients is tightly controlled by European Union regulations.
Together, this has meant he has so far been unable to find a company able to make and supply the drug for his trial, he said.
"Finding companies who could manufacture the drug and who are prepared to go through the regulatory hoops to get the license, which can take up to a year and triple the price, is proving very difficult," he said.
Nutt said regulatory authorities have a "primitive, old-fashioned attitude that Schedule 1 drugs could never have therapeutic potential", despite the fact that his research and the work done by other teams suggests such drugs may help treat some patients with psychiatric disorders.
Psilocybin - or "magic" - mushrooms grow naturally around the world and have been widely used since ancient times for religious rites and also for recreation.
Researchers in the United States have seen positive results in trials using MDMA, a pure form of the party drug ecstasy, in treating post-traumatic stress disorder.
"What we are trying to do is to tap into the reservoir of under-researched illegal drugs to see if we can find new and beneficial uses for them in people whose lives are often severely affected by illnesses such as depression," Nutt said.
The proposed trial would involve 60 patients with depression who have failed two previous treatments.
During two or three controlled sessions with a therapist, half would be given a synthetic form of psilocybin, and the other 30 a placebo. They would have guided talking therapy to explore negative thinking and issues troubling them, and doctors would follow them up for at least a year.
Nutt secured ethical approval for the trial in March.
In previous research, Nutt found that when healthy volunteers were injected with psilocybin, the drug switched off a part of the brain called the anterior cingulate cortex, which is known to be overactive in people with depression.
"Even in normal people, the more that part of the brain was switched off under the influence of the drug, the better they felt two weeks later. So there was a relationship between that transient switching off of the brain circuit and their subsequent mood,", he said. "This is the basis on which we want to run the trial."
Why Can’t We Publish Addresses Of New York Times Reporters? 2014 11 28 New York Times reporters Julie Bosman and Campbell Robertson published the address of Darren Wilson in the New York Times so here are their addresses.
GotNews.com strenuously objects to publishing the addresses of individuals who are being targeted with death threats.
GotNews.com published the address of Ebola patient Nina Pham so that people could avoid going to her Dallas apartment.
But it would ...
Terrorists? Interview with Varg Vikernes and Marie Cachet 2014 11 28
Marie Cachet and Varg Vikernes are what we call commonly ordinary people. However, for motives meanly political, the Ministry of the Interior decided to abuse its power to damage them ; "there is nothing more annoying than a low man placed in high position." (Roman saying) Today, Varg risks the eviction of the French territory without valid ground. Three very ...
The Coudenhove-Kalergi Plan - The Genocide Of The People Of Europe 2014 11 28 Mass immigration is a phenomenon, the causes of which are still cleverly concealed by the system, and the multicultural propaganda is trying to falsely portray it as inevitable. With this article we intend to prove once and for all, that this is not a spontaneous phenomenon. What they want to present as an inevitable outcome of modern life, is actually ...
Starbucks Supports Pro-GMO Company 2014 11 26 Another reason why you should not go to Starbucks.
Starbucks has an image of being a socially responsible, environmentally friendly company (Really?). In 2013, 95 percent of their coffee was ethically sourced, and their goal is to reach 100 percent by 2015.1
Other goals include reducing water consumption by 25 percent in their company-operated stores by 20152 and mobilizing their employees and ...
Group Polarization and the Fad of Ethno-masochism 2014 11 26
From "Group polarization: A critical review and meta-analysis". Journal of Personality and Social Psychology. 6 50 (6): 1141--1151
The psychology of White self hatred. Political correctness IS a mental disorder.
Group polarization: A critical review and meta-analysis.
Isenberg, Daniel J. the paper
Harvard Professor Noel Ignatiev talks about how to end the White race
The History of Political Correctness
The Narrative: The origins of Political ...